Successful treatment of autoimmune manifestations in MRL/l and MRL/n mice using total lymphoid irradiation (TLI).
The autoimmune manifestations of MRL-+/+ (MRL/n) and MRL/Mp-lpr/lpr (MRL/l) murine models of systemic lupus erythematosus (SLE) were successfully reversed following total lymphoid irradiation (TLI) therapy consisting of 8-12 daily fractions of 200 rad. Following radiotherapy the characteristic lymphadenopathy of MRL/l disappeared, proteinuria was 334 mg% compared to a peak of 2272 mg% in untreated controls, and the median survival time was prolonged to 423 days compared to 214 days in untreated mice. The albuminuria of TLI-treated MRL/n mice was 194 mg% compared to 1180 mg% in untreated controls. The survival of treated MRL/n mice was prolonged to a median of 389 as compared to 190 days in untreated controls. The effect of TLI on antiDNA antibodies in both MRL/l and MRL/n was less remarkable. However, the antiDNA activity reached normal levels in most long-living mice. The most impressive finding was complete reversal and/or prevention of the SLE-like glomerulonephritis in MRL/l mice as documented by light and electron microscopy. Immunomanipulation with TLI should be further evaluated as a possible treatment modality in intractable human autoimmune disorders.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D001853:Bone Marrow / Q000528:radiation effects; D016026:Bone Marrow Transplantation; D004247:DNA / Q000276:immunology; D007678:Kidney Glomerulus / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008206:Lymphatic Diseases / Q000532:radiotherapy; D008208:Lymphatic System / Q000528:radiation effects*; D051379:Mice; D008817:Mice, Mutant Strains; D011507:Proteinuria / Q000628:therapy
D000906:Antibodies; D004247:DNA